Pembrolizumab ISRCTN15819396 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 1/2

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2029-09-01

Primary-completion proxy

Executive view

ISRCTN15819396 evaluates Pembrolizumab in TROP2 NMR-positive non-small cell lung cancer. The disclosed sponsor is Cancer Research UK, the design is Interventional, and the geographic footprint is United Kingdom. The first listed primary endpoint is not reported, assessed over an unreported time frame.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for ISRCTN15819396 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider TROP2 NMR-positive non-small cell lung cancer landscape. Drug & Asset MCP drug_fetch was queried for Pembrolizumab, while Company & Deal Intelligence MCP organization_fetch was queried for Cancer Research UK.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
ISRCTN15819396	Pembrolizumab	Phase 1/2 / Recruiting	Cancer Research UK	United Kingdom		2029-09-01
NCT07692048	SYS-6010	Phase 1 / Not yet recruiting	Sichuan University	China	incidence of adverse effect From date of first administration up to approximately 3.5 years after…	2027-12-31
NCT07689643	[177Lu] Lu-RTX-2358	Early Phase 1 / Recruiting	Sponsor not reported	China	Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) From the first administration of [177Lu]Lu-RTX-2358 until 30 days aft…	2027-09-30
NCT07686445	AN4035	Phase 1 / Not yet recruiting	Hangzhou Adlai Nortye Biopharma Co. Ltd.	Australia	Nature and frequency of dose limiting toxicities (DLTs) 28 Days after first dose	2028-12-31
NCT07683832	Toripalimab	Early Phase 1 / Not yet recruiting	Nanjing Drum Tower Hospital	Geography not reported	Incidence and nature of dose-limiting toxicity (DLT) with ABO2109 monotherapy（Dose Exploration) From the first dose of ABO2109 through 21 days post-dose for each dos…	2028-12-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

ISRCTN15819396 is a Phase 1/2, recruiting study with not reported planned participants. Allocation is Randomized controlled trial, masking is Open (masking not used), and the intervention model is not reported.

The primary endpoint is “not reported” over “not reported.” The retrieved endpoint description is: 1. Dose for expansion determined following review of all clinically relevant data, including but not limited to toxicity, efficacy, PK and pharmacodynamic (PD) data. Evaluation of this endpoint will occur when all clinically relevant data in Module A have been reviewed by the sponsor, chief investigator and principal investigators. 2. Nature and frequency of dose-limiting toxicities (DLTs). DLTs are defined and assessed according to specific criteria in the trial protocol. Evaluation of this endpoint will occur when sufficient participants in Module A have completed the DLT observation period (first 21 days of a….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for TROP2 NMR-positive non-small cell lung cancer. These records do not establish direct evidence for ISRCTN15819396 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Pembrolizumab is indexed as Monoclonal antibody with PD-1 biology and a global stage of Approved. The asset profile lists Merck & Co., Inc. as an originator or developer.

Cancer Research UK is indexed in an unreported country with the website http://www.cancerresearchuk.org. Cancer Research UK pioneers life-saving research to bring forward the day when all cancers are cured. The record lists 20 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Pembrolizumab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: ISRCTN15819396
Protocol source: https://www.isrctn.com/ISRCTN15819396
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Pembrolizumab in TROP2 NMR-positive non-small cell lung cancer is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes the primary endpoint and 2029-09-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP